Search Within

Martin Stuart Tallman

Formats
  1. Journal Article (320)
  2. Meeting Abstract (278)
  3. Review (19)
  4. Editorial (9)
  5. Book Section (8)
  6. Research Letter (8)
  7. Guidelines (6)
  8. Correspondence (1)
Groups
  1. Adult Leukemia (649)
  2. Center for Hematologic Malignancies (649)
  3. Department of Medicine (649)
  4. Hematologic Malignancies, Division of (649)
  5. GSK Faculty (164)
  6. Executive Committee, Center for Hematologic Malignancies (156)

More Groups

People
  1. Ross Levine (131)
  2. Eytan Stein (114)
  3. Jae Park (79)
  4. Omar Abdel-Wahab (68)
  5. Sean Devlin (65)
  6. Dan Douer (50)

More People

Years
  1. 2025 (3)
  2. 2024 (7)
  3. 2023 (10)
  4. 2022 (26)
  5. 2021 (45)
  6. 2020 (51)

More Years

Publications
  1. Blood (272)
  2. Journal of Clinical Oncology (41)
  3. Leukemia Research (27)
  4. Blood Advances (26)
  5. Leukemia and Lymphoma (26)
  6. Haematologica (24)

More Publications

Publishers
  1. American Society of Hematology (298)
  2. Elsevier Inc. (43)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (38)
  5. Taylor & Francis Group (28)
  6. Elsevier Ltd (27)

More Publishers

Results (649)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive chemotherapy
    Meeting Abstract

    Feldman, E. J.; Lancet, J. E.; Kolitz, J. E.; Hogge, D.; Tallman, M. S.; Goldberg, S. L.; Kovacsovics, T.; Louie, A. C.; Cortes, J. E.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Stratification of CLL by ZAP-70 expression: Analysis of samples from the ECOG-led Intergroup Trial E2997
    Meeting Abstract

    Kaplan, D.; Sun, Z.; Tallman, M. S.; Flinn, I. W.; Xiao, W.; Caimi, P. F.; Kaye, N. M.; Lazarus, H. M.
    Blood (2013)

    Fulltext@MSK | Save
  • A high complete remission rate can be achieved in older patients (age >= 60) with acute lymphoblastic leukemia regardless of induction intensities: Single-institution experience at Memorial Sloan-Kettering Cancer Center
    Meeting Abstract

    Park, J. H.; Lee, S.; Devlin, S. M.; Tallman, M. S.; Douer, D.
    Blood (2013)

    Fulltext@MSK | Save
  • Predicting therapy-related acute myeloid leukemia by routine laboratory values: An analysis Of 126 patients with breast cancer referred for bone marrow biopsy at Memorial Sloan-Kettering Cancer Center
    Meeting Abstract

    Stein, E. M.; Hsu, M.; Goldrich, A.; Kishtagari, A.; Devlin, S. M.; Tallman, M. S.; Soff, G. A.; Parameswaran, R.
    Blood (2013)

    Fulltext@MSK | Save
  • Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: Toxicity results of the prospective US Intergroup Trial C10403 (Alliance)
    Meeting Abstract

    Advani, A. S.; Sanford, B.; Luger, S.; Devidas, M.; Larsen, E. C.; Liedtke, M.; Voorhees, P. M.; Foster, M. C.; Claxton, D. F.; Geyer, S.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Extramedullary disease is common in newly diagnosed AML but has no independent prognostic significance, including CNS involvement: Analysis of 3,522 AML patients treated on consecutive ECOG trials 1980-2008
    Meeting Abstract

    Ganzel, C.; Manola, J.; Douer, D.; Rowe, J. M.; Fernandez, H. F.; Paietta, E.; Litzow, M. R.; Lee, J. W.; Luger, S. M.; Lazarus, H. M.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Increased incidence of melanoma and non-melanoma skin cancers in patients with hairy cell leukemia: A single institution experience with 267 patients from Memorial Sloan-Kettering Cancer Center
    Meeting Abstract

    Watts, J. M.; Kishtagari, A.; Devlin, S.; Stein, E. M.; Park, J. H.; Lacouture, M. E.; Tallman, M.
    Blood (2013)

    Fulltext@MSK | Save
  • Azacitidine with or without entinostat for the treatment of therapy-related myeloid neoplasm: Further results of the E1905 North American Leukemia Intergroup Study
    Meeting Abstract

    Prebet, T.; Sun, Z.; Ketterling, R.; Greenberg, P. L.; Zeidan, A. M.; Litzow, M. R.; Gabrilove, J. L.; Erba, H. P.; Paietta, E.; Czader, M.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Phase II trial of the BRAF inhibitor, vemurafenib, in patients with BRAF mutant relapsed or refractory hairy cell leukemia
    Meeting Abstract

    Park, J. H.; Chung, S. S.; Chung, Y. R.; Won, H.; Teruya-Feldstein, J.; Berger, M.; Khawaja, T. T.; Lacouture, M. E.; Levine, R. L.; Abdel-Wahab, O.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Prognostic impact of MLL5 transcript levels on outcome of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: An International Consortium on Acute Promyelocytic Leukemia study
    Meeting Abstract

    Lucena-Araujo, A. R.; Kim, H. T.; Jacomo, R.; Melo, R. A.; Bittencourt, R.; Pasquini, R.; Pagnano, K. B.; Fagundes, E.; Chauffaille, M. d. L. L. F; Lima, A. S.; more...
    Blood (2013)

    Fulltext@MSK | Save